Assay News and Research

RSS

Efficacy and safety of a 3rd dose of mRNA-1273 SARS-CoV-2 vaccine

In a recent study posted to the Research Square* preprint server, researchers tested the safety and immunogenicity of a third dose of coronavirus disease 2019 (COVID-19) prototype messenger ribonucleic acid (mRNA)-1273 versus a variant vaccine and a bivalent vaccine formulation.

5 May 2022

Evaluating a third SARS-CoV-2 mRNA vaccine in anti-CD20-treated patients

In a new study, researchers assessed the efficacy of a third dose of COVID-19 vaccine in anti-CD20 antibody-treated individuals.

4 May 2022

Phase 2 clinical trial of COVID-19 convalescent plasma with high antibody titers

Researchers determined the threshold neutralizing antibody titer for effective COVID-19 convalescent plasma therapy.

4 May 2022

Researchers reveal the mechanism of action of century-old BCG vaccine

The century-old Bacille Calmette-Guérin (BCG) vaccine against tuberculosis is one of the world's oldest and most widely used vaccines, used to immunize 100 million newborns every year. Given in countries with endemic TB, it has surprisingly been found to protect newborns and young infants against multiple bacterial and viral infections unrelated to TB. There's even some evidence that it can reduce severity of COVID-19.

4 May 2022

Pets living in households with COVID-19 are high likely to seroconvert and become ill

In a recent study published in the journal Emerging Infectious Diseases, researchers investigated whether pet dogs and cats in the households of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected humans were at risk of infection.

3 May 2022

SARS-CoV-2 inhibition mediated by cellular nucleic acid-binding protein

A recent study under review at Nature Portfolio and posted to the Research Square* preprint server depicted how cellular nucleic acid-binding protein (CNBP) inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

3 May 2022

Efficacy of affinity resin containing Galanthus nivalis agglutinin against SARS-CoV-2

A new study demonstrated the efficacy of the Galanthus nivalis agglutinin (GNA)-incorporated affinity resin against various SARS-CoV-2 variants.

3 May 2022

Neutralizing antibodies produced following COVID-19 BNT162b2 vaccine found to activate complement cascade

Researchers investigated the complement component 1q (C1q) binding and subsequent complement activation by neutralizing antibodies (nAbs) produced following COVID-19 vaccination.

2 May 2022

SARS-CoV-2 viral shedding varies widely in asymptomatic and mildly ill patients

In a recent study published in the Nature Microbiology journal, researchers assessed the longitudinal viral dynamics in asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

1 May 2022

Antibody cocktail shows synergetic effects against SARS-CoV-2 Omicron in vitro and in vivo

A recent research paper posted to the bioRxiv* preprint server demonstrated that a cocktail of two synergetic antibodies extensively neutralized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, including Omicron BA.1 and BA.2.

1 May 2022

Study reports an orally available SARS-CoV-2 Mpro inhibitor with potent in vivo antiviral activity

Researchers examined the efficiency of the main protease (Mpro) inhibitor against SARS-CoV-2.

29 Apr 2022

Sartorius Launches the Octet® SF3 SPR System, Strengthening its Leadership in Advanced Label-Free Bioanalytics

Sartorius Octet® becomes the only brand to offer the two leading label-free technologies: BLI and SPR.

From Sartorius 29 Apr 2022

Study shows polysaccharides of seaweed and abalone inhibit SARS-CoV-2 in vitro

A new study published in Marine Drugs evaluated the inhibitory effect of three polysaccharides, crude polysaccharide from Hizikia fusiforme (CPHF), crude polysaccharide from Sargassum horneri (CPSH), and crude polysaccharide from abalone viscera (CPAV) on the propagation of SARS-CoV-2 in vitro.

28 Apr 2022

Therapeutic promise of CAR-T cell bispecific engagers against SARS-CoV-2

A new paper describes a novel method, using a specific molecule to engage T cell receptors and the virus receptor, the angiotensin-converting enzyme 2, at the same time.

28 Apr 2022

Identification of a SARS-CoV-2 neutralizing human monoclonal antibody with a remarkable broad-spectrum neutralization and protection efficacy

Researchers identified a human monoclonal antibody (mAb), 87G7, with in vitro neutralizing activity against several SARS-CoV-2 VOCs, including Alpha, Beta, Gamma, Delta, and Omicron.

28 Apr 2022

Discovery of novel antibody that targets shared epitope on SARS-CoV-2 variants

Researchers assessed the antibody responses elicited by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and defined the epitopes shared by them.

28 Apr 2022

Green tea catechin as pan-coronavirus attachment inhibitor

In a recent study posted to the Research Square* preprint server, researchers assessed the impact of green tea catechin epigallocatechin gallate (EGCG) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

27 Apr 2022

Comparative analysis of transcriptional responses across 13 different vaccines

A new study aimed to carry out a comparative analysis of transcriptional responses from 820 healthy young adults across 13 different vaccines.

27 Apr 2022

St. John's wort extract shows potent antiviral activity against SARS-CoV-2 and its variants

Scientists from Germany have recently identified Hypericum perforatum, a widespread herbal plant known as St. John's wort, as a potential antiviral agent against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study is published in the journal Pharmaceuticals.

27 Apr 2022

Asymptomatic SARS-CoV-2 infection among research personnel: Study

A recent research paper published in the journal Public Library of Science (PLOS) ONE analyzed asymptomatic coronavirus disease 2019 (COVID-19) in personnel engaged in academic study.

26 Apr 2022

Assay News and Research

Efficacy and safety of a 3rd dose of mRNA-1273 SARS-CoV-2 vaccine

Evaluating a third SARS-CoV-2 mRNA vaccine in anti-CD20-treated patients

Phase 2 clinical trial of COVID-19 convalescent plasma with high antibody titers

Researchers reveal the mechanism of action of century-old BCG vaccine

Pets living in households with COVID-19 are high likely to seroconvert and become ill

SARS-CoV-2 inhibition mediated by cellular nucleic acid-binding protein

Efficacy of affinity resin containing Galanthus nivalis agglutinin against SARS-CoV-2

Neutralizing antibodies produced following COVID-19 BNT162b2 vaccine found to activate complement cascade

SARS-CoV-2 viral shedding varies widely in asymptomatic and mildly ill patients

Antibody cocktail shows synergetic effects against SARS-CoV-2 Omicron in vitro and in vivo

Study reports an orally available SARS-CoV-2 Mpro inhibitor with potent in vivo antiviral activity

Sartorius Launches the Octet® SF3 SPR System, Strengthening its Leadership in Advanced Label-Free Bioanalytics

Study shows polysaccharides of seaweed and abalone inhibit SARS-CoV-2 in vitro

Therapeutic promise of CAR-T cell bispecific engagers against SARS-CoV-2

Identification of a SARS-CoV-2 neutralizing human monoclonal antibody with a remarkable broad-spectrum neutralization and protection efficacy

Discovery of novel antibody that targets shared epitope on SARS-CoV-2 variants

Green tea catechin as pan-coronavirus attachment inhibitor

Comparative analysis of transcriptional responses across 13 different vaccines

St. John's wort extract shows potent antiviral activity against SARS-CoV-2 and its variants

Asymptomatic SARS-CoV-2 infection among research personnel: Study

eBook: Using iPSCs models for human disease research and drug discovery eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News